WPC 2026 Update: The Current State of the Science - Why Everyone Is Talking About Alpha-Synuclein?
What alpha-synuclein is, why it matters, how it may spread through the nervous system, and why researchers believe it could hold the key to earlier diagnosis and new treatments.
If there was one scientific topic that seemed to appear in almost every lecture I attended at the World Parkinson Congress, it was alpha-synuclein.
Researchers discussed it in sessions on genetics. They discussed it in sessions on biomarkers. They discussed it in sessions on disease-modifying therapies, early diagnosis, neuroinflammation, and precision medicine.
In many ways, alpha-synuclein has become the center of modern Parkinson's disease research.
But what exactly is it, and why is everyone so interested in it?
The answer is both fascinating and surprisingly complicated.
First, What Is Alpha-Synuclein?
Alpha-synuclein is a protein that naturally exists in the brain and nervous system. In fact, it is one of the most abundant proteins found in neurons.
For many years, scientists didn't fully understand what it did. We now know that alpha-synuclein plays important roles in communication between nerve cells.
Specifically, it helps regulate the release and recycling of neurotransmitters—the chemical messengers that allow one nerve cell to communicate with another.
You can think of alpha-synuclein as one of the many workers helping to keep communication flowing smoothly at the synapse, the tiny gap where neurons exchange information.
In a healthy brain, alpha-synuclein appears to help organize synaptic activity, support dopamine signaling, and maintain efficient communication between neurons.
In other words, alpha-synuclein is not inherently "bad." It is a normal and important part of brain function.
What Happens in Parkinson's Disease?
The problem begins when alpha-synuclein changes shape.
Proteins must fold into specific three-dimensional structures to function properly. In Parkinson's disease, alpha-synuclein can misfold and begin sticking to other alpha-synuclein proteins.
Over time, these misfolded proteins clump together and form aggregates.
Eventually, these aggregates contribute to the formation of Lewy bodies—the abnormal protein deposits that are considered one of the hallmark pathological features of Parkinson's disease.
Researchers believe these protein clumps interfere with normal cellular function in several ways.
They may disrupt communication between neurons, interfere with cellular waste disposal systems, impair mitochondrial function, trigger inflammation, and contribute to eventual neuronal death.
Importantly, alpha-synuclein aggregation doesn't appear to affect only dopamine-producing neurons. It has been found throughout multiple regions of the nervous system, helping explain why Parkinson's disease involves much more than tremor and movement symptoms.
Does Alpha-Synuclein Spread?
One of the most intriguing theories discussed at the conference was the idea that alpha-synuclein may spread through the nervous system in a "prion-like" manner.
Prions are abnormal proteins capable of causing other proteins to misfold.
Researchers now believe misfolded alpha-synuclein may behave somewhat similarly.
The theory suggests that once one alpha-synuclein protein misfolds, it may encourage neighboring proteins to misfold as well. Those proteins may then spread to nearby cells and continue the process.
Over many years, this could potentially explain how pathology progresses through different regions of the nervous system.
While the exact mechanisms remain under investigation, growing evidence supports the idea that alpha-synuclein may move from cell to cell and contribute to the spread of disease.
Could Parkinson's Begin Outside the Brain?
This is where things become especially interesting.
Researchers are increasingly exploring the possibility that Parkinson's disease may not always begin in the brain itself.
Alpha-synuclein aggregates have been identified in the:
Gut
Enteric nervous system
Salivary glands
Skin
Olfactory system
Autonomic nervous system
Some researchers now propose that, in certain individuals, alpha-synuclein pathology may begin in the body and gradually spread toward the brain.
This concept is often referred to as the "body-first" hypothesis.
Others appear to follow a "brain-first" pattern, where pathology begins centrally and later spreads outward.
One of the major themes at WPC was that Parkinson's disease may not follow a single pathway for every individual.
Understanding these differences may eventually help explain why people experience different symptoms, progress at different rates, and respond differently to treatment.
Why Alpha-Synuclein Matters for Earlier Diagnosis
One of the biggest challenges in Parkinson's disease is that diagnosis typically occurs after substantial damage has already taken place.
Many researchers estimate that symptoms may not appear until roughly half of dopamine-producing neurons have already been lost.
This means biological changes may be occurring for years—or even decades—before diagnosis.
Because alpha-synuclein appears so early in the disease process, researchers are working intensely to develop tests capable of detecting abnormal alpha-synuclein before significant symptoms emerge.
This is where one of the most exciting developments in Parkinson's research comes in.
Seed Amplification Assays: A Potential Game Changer
Several lectures focused on a technology called a Seed Amplification Assay (SAA).
Rather than simply measuring how much alpha-synuclein is present, these tests look for whether alpha-synuclein behaves abnormally and can "seed" further aggregation.
Think of it as the difference between counting the number of people in a room versus identifying who is actively causing trouble.
Current seed amplification assays can detect abnormal alpha-synuclein in:
Cerebrospinal fluid (CSF)
Skin biopsy samples
Researchers are now working aggressively to develop reliable blood-based testing.
If successful, blood testing could dramatically improve screening, diagnosis, disease staging, and clinical trial recruitment.
Many speakers described blood-based alpha-synuclein testing as one of the major goals of the next decade.
But Here's the Controversy
As exciting as alpha-synuclein research has become, it is not without debate.
One of the most interesting discussions at WPC centered around a fundamental question:
Is alpha-synuclein actually causing Parkinson's disease, or is it simply a marker of broader neurodegenerative processes?
This question remains unresolved.
Researchers discussed several observations that complicate the picture:
Some individuals have positive alpha-synuclein seed amplification assays but do not have Parkinson's disease.
Some individuals with Parkinson's disease have negative alpha-synuclein testing.
Some people accumulate substantial alpha-synuclein pathology without developing symptoms.
Others develop symptoms with relatively modest pathology.
These findings suggest alpha-synuclein may be only one piece of a much larger biological puzzle.
Many researchers now believe Parkinson's disease likely results from interactions among multiple biological processes, including:
Alpha-synuclein aggregation
Dopamine neuron loss
Mitochondrial dysfunction
Neuroinflammation
Genetic susceptibility
Environmental influences
In other words, alpha-synuclein may be critically important without necessarily being the entire story.
What About Alpha-Synuclein Medications?
If alpha-synuclein is involved in Parkinson's disease, can we target it therapeutically?
Researchers are certainly trying.
Several strategies are currently under investigation:
Preventing alpha-synuclein aggregation
Breaking apart existing aggregates
Enhancing clearance of abnormal protein
Blocking cell-to-cell spread
Reducing alpha-synuclein production
One of the most widely discussed therapies is Prasinezumab, an antibody designed to bind alpha-synuclein and potentially reduce its spread.
While early trials did not meet their primary endpoints, some long-term analyses suggested participants receiving the medication may have progressed more slowly over time.
This has kept the field interested and ongoing studies continue.
Importantly, many speakers reminded attendees that early trial failures are common in medicine.
In fact, several medications we now consider standard therapies initially failed early studies before later becoming successful treatments.
Research rarely moves in a straight line.
The Bigger Picture
The most important takeaway from the World Parkinson Congress wasn't that alpha-synuclein is the answer to Parkinson's disease.
It was that alpha-synuclein has become one of the most powerful tools we currently have for understanding Parkinson's disease.
Whether it ultimately proves to be the primary driver of disease, one contributor among many, or simply a valuable biomarker, it is helping researchers answer some of the biggest questions in the field.
How does Parkinson's disease begin?
Can we diagnose it earlier?
Can we identify different biological subtypes?
Can we target disease before significant neurodegeneration occurs?
And can we finally develop therapies that do more than simply treat symptoms?
Those questions remain unanswered.
But after listening to researchers from around the world discuss alpha-synuclein from every possible angle, one thing became clear:
The future of Parkinson's disease research—and perhaps the future of Parkinson's treatment—is becoming increasingly biological, increasingly personalized, and increasingly focused on understanding the role of proteins like alpha-synuclein long before symptoms ever begin.
Part 3: Is Parkinson's Genetic?
A look at the genes most strongly linked to Parkinson's disease—including LRRK2, GBA1, PINK1, and Parkin—and how genetics is driving a new era of targeted therapies.
